563 related articles for article (PubMed ID: 33483370)
1. Gut Microbiota Condition the Therapeutic Efficacy of Trastuzumab in HER2-Positive Breast Cancer.
Di Modica M; Gargari G; Regondi V; Bonizzi A; Arioli S; Belmonte B; De Cecco L; Fasano E; Bianchi F; Bertolotti A; Tripodo C; Villani L; Corsi F; Guglielmetti S; Balsari A; Triulzi T; Tagliabue E
Cancer Res; 2021 Apr; 81(8):2195-2206. PubMed ID: 33483370
[TBL] [Abstract][Full Text] [Related]
2. Immune Signatures Following Single Dose Trastuzumab Predict Pathologic Response to PreoperativeTrastuzumab and Chemotherapy in HER2-Positive Early Breast Cancer.
Varadan V; Gilmore H; Miskimen KL; Tuck D; Parsai S; Awadallah A; Krop IE; Winer EP; Bossuyt V; Somlo G; Abu-Khalaf MM; Fenton MA; Sikov W; Harris LN
Clin Cancer Res; 2016 Jul; 22(13):3249-59. PubMed ID: 26842237
[TBL] [Abstract][Full Text] [Related]
3. Antibiotic-associated dysbiosis affects the ability of the gut microbiota to control intestinal inflammation upon fecal microbiota transplantation in experimental colitis models.
Strati F; Pujolassos M; Burrello C; Giuffrè MR; Lattanzi G; Caprioli F; Troisi J; Facciotti F
Microbiome; 2021 Feb; 9(1):39. PubMed ID: 33549144
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant Therapy for HER2-positive Breast Cancer.
Wuerstlein R; Harbeck N
Rev Recent Clin Trials; 2017; 12(2):81-92. PubMed ID: 28164759
[TBL] [Abstract][Full Text] [Related]
5. Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.
Perez EA; de Haas SL; Eiermann W; Barrios CH; Toi M; Im YH; Conte PF; Martin M; Pienkowski T; Pivot XB; Burris HA; Stanzel S; Patre M; Ellis PA
BMC Cancer; 2019 May; 19(1):517. PubMed ID: 31146717
[TBL] [Abstract][Full Text] [Related]
6. Exposure-response analyses of trastuzumab emtansine in patients with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane.
Li C; Wang B; Chen SC; Wada R; Lu D; Wang X; Polhamus D; French J; Vadhavkar S; Strasak A; Smitt M; Joshi A; Samant M; Quartino A; Jin J; Girish S
Cancer Chemother Pharmacol; 2017 Dec; 80(6):1079-1090. PubMed ID: 29022084
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.
De Mattos-Arruda L; Bottai G; Nuciforo PG; Di Tommaso L; Giovannetti E; Peg V; Losurdo A; Pérez-Garcia J; Masci G; Corsi F; Cortés J; Seoane J; Calin GA; Santarpia L
Oncotarget; 2015 Nov; 6(35):37269-80. PubMed ID: 26452030
[TBL] [Abstract][Full Text] [Related]
8. Improved Natural Killer cell activity and retained anti-tumor CD8(+) T cell responses contribute to the induction of a pathological complete response in HER2-positive breast cancer patients undergoing neoadjuvant chemotherapy.
Muraro E; Comaro E; Talamini R; Turchet E; Miolo G; Scalone S; Militello L; Lombardi D; Spazzapan S; Perin T; Massarut S; Crivellari D; Dolcetti R; Martorelli D
J Transl Med; 2015 Jun; 13():204. PubMed ID: 26116238
[TBL] [Abstract][Full Text] [Related]
9. Early Stage HER2-Positive Breast Cancers Not Achieving a pCR From Neoadjuvant Trastuzumab- or Pertuzumab-Based Regimens Have an Immunosuppressive Phenotype.
Force J; Howie LJ; Abbott SE; Bentley R; Marcom PK; Kimmick G; Westbrook K; Sammons SL; Parks M; Topping DL; Emerson R; Broadwater G; Hyslop T; Blackwell KL; Nair SK
Clin Breast Cancer; 2018 Oct; 18(5):410-417. PubMed ID: 29615305
[TBL] [Abstract][Full Text] [Related]
10. The Probiotic Compound VSL#3 Modulates Mucosal, Peripheral, and Systemic Immunity Following Murine Broad-Spectrum Antibiotic Treatment.
Ekmekciu I; von Klitzing E; Fiebiger U; Neumann C; Bacher P; Scheffold A; Bereswill S; Heimesaat MM
Front Cell Infect Microbiol; 2017; 7():167. PubMed ID: 28529928
[TBL] [Abstract][Full Text] [Related]
11. Phase II Study of Nab-paclitaxel Plus Cyclophosphamide Plus Trastuzumab Neoadjuvant Chemotherapy in Early HER-2-positive Breast Cancer.
Ogino M; Fujii T; Koibuchi Y; Nakazawa Y; Takata D; Shirabe K
Anticancer Res; 2021 Aug; 41(8):3899-3904. PubMed ID: 34281852
[TBL] [Abstract][Full Text] [Related]
12. TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer.
Mercogliano MF; De Martino M; Venturutti L; Rivas MA; Proietti CJ; Inurrigarro G; Frahm I; Allemand DH; Deza EG; Ares S; Gercovich FG; Guzmán P; Roa JC; Elizalde PV; Schillaci R
Clin Cancer Res; 2017 Feb; 23(3):636-648. PubMed ID: 27698002
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of HER2 inhibitors in combination with or without pertuzumab for HER2-positive breast cancer: a systematic review and meta-analysis.
Chen S; Liang Y; Feng Z; Wang M
BMC Cancer; 2019 Oct; 19(1):973. PubMed ID: 31638935
[TBL] [Abstract][Full Text] [Related]
14. Use of Trastuzumab for Neoadjuvant Therapy of HER2+ Breast Cancer - 5-Years of Experience in a Single Clinic.
Zuazana B; Luboš P; Renata C
Klin Onkol; 2018; 31(3):191-199. PubMed ID: 30441972
[TBL] [Abstract][Full Text] [Related]
15. The interaction between carcinoembryonic antigen-related cell adhesion molecule 6 and human epidermal growth factor receptor 2 is associated with therapeutic efficacy of trastuzumab in breast cancer.
Iwabuchi E; Miki Y; Kanai A; Miyashita M; Kijima G; Hirakawa H; Suzuki T; Ishida T; Sasano H
J Pathol; 2018 Nov; 246(3):379-389. PubMed ID: 30058236
[TBL] [Abstract][Full Text] [Related]
16. Gut microbiota modulates adoptive cell therapy via CD8α dendritic cells and IL-12.
Uribe-Herranz M; Bittinger K; Rafail S; Guedan S; Pierini S; Tanes C; Ganetsky A; Morgan MA; Gill S; Tanyi JL; Bushman FD; June CH; Facciabene A
JCI Insight; 2018 Feb; 3(4):. PubMed ID: 29467322
[TBL] [Abstract][Full Text] [Related]
17. HER2-positive breast cancer.
Loibl S; Gianni L
Lancet; 2017 Jun; 389(10087):2415-2429. PubMed ID: 27939064
[TBL] [Abstract][Full Text] [Related]
18. Association of Depressed Anti-HER2 T-Helper Type 1 Response With Recurrence in Patients With Completely Treated HER2-Positive Breast Cancer: Role for Immune Monitoring.
Datta J; Fracol M; McMillan MT; Berk E; Xu S; Goodman N; Lewis DA; DeMichele A; Czerniecki BJ
JAMA Oncol; 2016 Feb; 2(2):242-6. PubMed ID: 26719971
[TBL] [Abstract][Full Text] [Related]
19. Predictive factors of pathologic complete response of HER2-positive breast cancer after preoperative chemotherapy with trastuzumab: development of a specific predictor and study of its utilities using decision curve analysis.
Jankowski C; Guiu S; Cortet M; Charon-Barra C; Desmoulins I; Lorgis V; Arnould L; Fumoleau P; Coudert B; Rouzier R; Coutant C; Reyal F
Breast Cancer Res Treat; 2017 Jan; 161(1):73-81. PubMed ID: 27807808
[TBL] [Abstract][Full Text] [Related]
20. Anti-HER2 CD4(+) T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer.
Datta J; Berk E; Xu S; Fitzpatrick E; Rosemblit C; Lowenfeld L; Goodman N; Lewis DA; Zhang PJ; Fisher C; Roses RE; DeMichele A; Czerniecki BJ
Breast Cancer Res; 2015 May; 17(1):71. PubMed ID: 25997452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]